Workflow
GeoVax Appoints Teresa Lambe, Acclaimed Professor of Vaccinology and Immunology at the Oxford Vaccine Group, to Its Scientific Advisory Board
GeoVax LabsGeoVax Labs(US:GOVX) GlobeNewswire News Room·2024-08-08 13:00

Core Insights - GeoVax Labs, Inc. has appointed Professor Teresa Lambe to its Scientific Advisory Board, enhancing its leadership in vaccine development [1][4] - Professor Lambe is recognized for her pivotal role in the Oxford/AstraZeneca COVID-19 vaccine program and has received multiple prestigious awards for her contributions to science and public health [2][3] Company Overview - GeoVax is a clinical-stage biotechnology company focused on developing vaccines for infectious diseases and therapies for solid tumor cancers [5] - The company's lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine, which is currently undergoing a 10,000-participant Phase 2b clinical trial funded by BARDA [5] - In oncology, GeoVax is evaluating Gedeptin®, a novel oncolytic solid tumor gene-directed therapy, in a multicenter Phase 1/2 clinical trial for advanced head and neck cancers [5] Research and Development Focus - Professor Lambe's research aims to design vaccination strategies based on understanding the protective immune response post-infection, with ongoing projects targeting outbreak pathogens such as Ebola and Marburg viruses [3] - GeoVax's vaccine development efforts align with Professor Lambe's expertise, particularly in addressing high-risk and immunocompromised populations [4]